Black Diamond Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 12, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
The company has elected not to include summary information.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Black Diamond Therapeutics, Inc. | ||
| Date: March 12, 2024 | By: | /s/ Mark A. Velleca |
|---|---|---|
| Mark A. VellecaPresident and Chief Executive Officer | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose individual signature appears below hereby authorizes and appoints Mark A. Velleca and Brent Hatzis-Schoch, and each of them, with full power of substitution and re-substitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities indicated on the 12th day of March, 2024.
| Signature | Title |
|---|---|
| /s/ Mark A. Velleca | President, Chief Executive Officer, Chairman and Director(Principal Executive Officer) |
| Mark A. Velleca | |
| /s/ Fang Ni | Chief Business Officer and Chief Financial Officer(Principal Financial Officer) |
| Fang Ni | |
| /s/ Erika Jones | Senior Vice President, Finance and Corporate Controller(Principal Accounting Officer) |
| Erika Jones | |
| /s/ Ali Behbahani | Director |
| Ali Behbahani | |
| /s/ Samarth Kulkarni | Director |
| Samarth Kulkarni | |
| /s/ Alexander Mayweg | Director |
| Alexander Mayweg | |
| /s/ Garry E. Menzel | Director |
| Garry E. Menzel | |
| /s/ Kapil Dhingra | Director |
| Kapil Dhingra | |
| /s/ Wendy Dixon | Director |
| Wendy Dixon | |
| /s/ David M. Epstein | Director |
| David M. Epstein | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.